XML 56 R45.htm IDEA: XBRL DOCUMENT v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue recognition (Details)
12 Months Ended
Feb. 05, 2024
item
Dec. 31, 2024
USD ($)
item
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Revenue recognition        
Estimated contractual allowances   $ 2,100,000 $ 2,100,000  
License revenue payable to patent owner, as a percent   50.00%    
Sales, net   $ 33,049,533 43,596,926 $ 94,818,938
Licensing fees        
Revenue recognition        
Sales, net   189,000 778,000 0
Syringes        
Revenue recognition        
Sales, net   22,629,888 34,155,340 86,738,861
Blood Collection Products        
Revenue recognition        
Sales, net   1,425,607 1,926,571 2,953,849
EasyPoint Needles        
Revenue recognition        
Number of units subject to recall | item 477,600      
Estimated expense related to recall   0 116,000  
Sales, net   8,948,186 7,248,742 4,674,278
Other Products        
Revenue recognition        
Sales, net   45,852 266,273 451,950
U.S. sales (excluding U.S. government)        
Revenue recognition        
Sales, net       36,492,275
U.S. sales (excluding U.S. government) | Syringes        
Revenue recognition        
Sales, net       29,283,122
U.S. sales (excluding U.S. government) | Blood Collection Products        
Revenue recognition        
Sales, net       2,685,785
U.S. sales (excluding U.S. government) | EasyPoint Needles        
Revenue recognition        
Sales, net       4,481,202
U.S. sales (excluding U.S. government) | Other Products        
Revenue recognition        
Sales, net       42,166
Sales to U.S. government        
Revenue recognition        
Sales, net       15,731,136
Sales to U.S. government | Syringes        
Revenue recognition        
Sales, net       15,731,136
U.S. sales        
Revenue recognition        
Sales, net   29,374,145 34,599,754 36,492,275
U.S. sales | Syringes        
Revenue recognition        
Sales, net   19,491,747 26,119,940  
U.S. sales | Blood Collection Products        
Revenue recognition        
Sales, net   1,259,289 1,414,783  
U.S. sales | EasyPoint Needles        
Revenue recognition        
Sales, net   8,595,794 7,031,798  
U.S. sales | Other Products        
Revenue recognition        
Sales, net   27,315 33,233  
North and South America sales (excluding U.S.)        
Revenue recognition        
Sales, net   1,960,769 6,085,166 29,126,820
North and South America sales (excluding U.S.) | Syringes        
Revenue recognition        
Sales, net   1,895,393 5,858,726 28,720,378
North and South America sales (excluding U.S.) | Blood Collection Products        
Revenue recognition        
Sales, net   96    
North and South America sales (excluding U.S.) | EasyPoint Needles        
Revenue recognition        
Sales, net   59,040   2,608
North and South America sales (excluding U.S.) | Other Products        
Revenue recognition        
Sales, net   6,240 226,440 403,834
Other international sales        
Revenue recognition        
Sales, net   1,714,619 2,912,006 13,468,707
Other international sales | Syringes        
Revenue recognition        
Sales, net   1,242,748 2,176,674 13,004,225
Other international sales | Blood Collection Products        
Revenue recognition        
Sales, net   166,222 511,788 268,064
Other international sales | EasyPoint Needles        
Revenue recognition        
Sales, net   293,352 216,944 190,468
Other international sales | Other Products        
Revenue recognition        
Sales, net   $ 12,297 $ 6,600 $ 5,950
U.S.        
Revenue recognition        
Period for return of incorrect domestic shipments   10 days    
Number of times overstocking returns are limited | item   2    
Period for return of product due to overstock   12 months    
Maximum percentage of distributor's total purchase for the prior 12-month period   1.00%